483 articles with Evotec AG
Evotec SE announced that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.
Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer.
Partnership Aims to Replicate Successful Milestone Achievement from Revolutionary Joint Drug Discovery Program in Colorectal Cancer
Evotec SE announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company's financial performance.
Evotec SE announced that the wholly-owned Seattle-based company Just - Evotec Biologics initiated the construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington.
Evotec and Bayer Announce New Alliance Focusing on Drug Discovery for Polycystic Ovary Syndrome With Novel Targets From Celmatix
New five-year, multi-target alliance aims to translate first-in-class science and drug discovery into new drugs for polycystic ovary syndrome
Adding cell types supports discovery of disease-modifying therapies for neurodegenerative diseases and triggers US$ 6M payment to Evotec
Evotec Expands Service Agreement With Sanofi To Create A Centralised Global Sample Management Hub In Toulouse
Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi.
Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics, announced a strategic alliance with Evotec, a global leader in drug discovery and development.
Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics
Vifor picks up external R&D capabilities for its own nephrology pipeline and Evotec gains a commercial partner via outlicensing all kidney disease assets that are developed from the joint venture.
First academic bridge partnership in Israel aims to translate early-stage research from the Hebrew University ("HU") of jerusalem into industrial drug development projects
Biocon Biologics in-licenses an early-stage biosimilar asset, will undertake development, manufacturing and commercialization under its own label
The Goal Is To Develop Novel Pre-clinical Programmes For High Unmet Medical Need Conditions For Women
Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.
Germany-based Evotec is partnering with Japan’s Takeda Pharmaceutical to develop at least five drug discovery programs across a broad range of indications.
Evotec SE reported financial results and corporate updates for the first half of 2019.
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents.
Evotec SE announced that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough.
Acquired assets from NCARDIA AG include IP portfolio, IPSC-based cellular products and an experienced stem cell biology team